Synonym: 16,17-Butylidenebis(oxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione
CAS Number: 51333-22-3
Empirical Formula (Hill Notation): C25H34O6
Molecular Weight: 430.53
MDL Number: MFCD00083259
Linear Formula: C25H34O6
Product Type: Chemical
| format |
neat |
| grade |
pharmaceutical primary standard |
| InChI |
1S/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h8-10,16-18,20-22,26,28H,4-7,11-13H2,1-3H3/t16-,17-,18-,20+,21?,22+,23-,24-,25+/m0/s1 |
| InChI key |
VOVIALXJUBGFJZ-KWVAZRHASA-N |
| manufacturer/tradename |
BP |
| SMILES string |
[H][C@@]12CCC3=CC(=O)C=C[C@]3(C)[C@@]1([H])[C@@H](O)C[C@@]4(C)[C@@]2([H])C[C@H]5OC(CCC)O[C@@]45C(=O)CO |
| Biochem/physiol Actions: |
Budesonide is a second generation glucocorticoid with low systemic absorption. It is used as an anti-inflammatory agent in the treatment of asthma, rhinitis, and inflammatory bowel disease. It inhibits the expression of chemokine mRNA and production of eotaxin and RANTES protein in primary human bronchial epithelial cells. Budesonide is currently in clinical trials for the prevention of lung cancer. It shows inhibitory effects on benzo[a]pyrene-induced carcinogenesis of the lung in mice. |
| General description: |
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia. |
| Other Notes: |
Sales restrictions may apply. |
| Packaging: |
Unit quantity: 110 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity please visit British Pharmacopoeia   |
| RIDADR |
NONH for all modes of transport |
| WGK Germany |
WGK 3 |
| Flash Point(F) |
Not applicable |
| Flash Point(C) |
Not applicable |
